NEW YORK – Chinese drug developer InnoCare Pharma on Wednesday said that it has dosed the first patient in the US in a Phase II study of its pan-FGFR inhibitor ICP-192 in FGFR-aberrant cancers.
NEW YORK – Chinese drug developer InnoCare Pharma on Wednesday said that it has dosed the first patient in the US in a Phase II study of its pan-FGFR inhibitor ICP-192 in FGFR-aberrant cancers.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.